[Federal Register Volume 80, Number 96 (Tuesday, May 19, 2015)]
[Notices]
[Pages 28633-28634]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-12005]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Biomarkers for Acute
Ischemic Stroke
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
404, that the National Institutes of Health (NIH), Department of Health
and Human Services (HHS), is contemplating the grant of an exclusive
license, to practice the inventions embodied in the following patent
applications:
1. U.S. Provisional Patent Application No. 61/307,233, filed 23
February 2010
HHS Ref. No.: E-023-2010/0-US-01
Titled: Biomarkers for Acute Ischemic Stroke
2. PCT Patent Application No. PCT/US2011/025748, filed 22 February 2011
HHS Ref. No.: E-023-2010/0-PCT-02
Titled: Biomarkers for Acute Ischemic Stroke
3. U.S. Patent Application No. 13/580,571, filed 22 August 2012
HHS Ref. No.: E-023-2010/0-US-03
Titled: Biomarkers for Acute Ischemic Stroke
to VuEssence, Inc., a company incorporated under the laws of the State
of Florida having its headquarters in
[[Page 28634]]
Odessa, Florida. The patent rights in these inventions have been
assigned to the United States of America.
DATES: Only written comments and/or applications for a license received
by the NIH Office of Technology Transfer on or before June 18, 2015
will be considered.
ADDRESSES: Requests for a copy of the patent applications, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Jaime M. Greene, M.S., Office of Technology
Transfer, National Institutes of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-5559; Email:
[email protected]; Facsimile: (301) 402-0220. A signed
confidentiality nondisclosure agreement will be required to receive
copies of any patent applications that have not been published or
issued by the United States Patent and Trademark Office or the World
Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: This technology is directed to gene
biomarkers for the diagnosis and potential treatment of acute ischemic
stroke. Stroke is the third leading cause of death in the United
States, of which 87% are ischemic stroke and result in death within 30
days in 8-12% of the cases. Currently, recombinant tissue plasminogen
activator (rtPA, trade name alteplase), is the only FDA approved
ischemic stroke treatment, and it is only effective when administered
to patients within three hours from the onset of symptoms.
Unfortunately, the median time from stroke symptom onset to
presentation to the emergency department is 3-6 hours. Although
advances in neuroimaging and clinical management have helped with
patient survival rates, these techniques are not infallible and at
times result in misdiagnosis. The biomarkers identified in this
technology may be used to develop a diagnostic testing device for
determining stroke subtype in the field.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part
404. The prospective exclusive license may be granted unless, within
thirty (30) days from the date of this published notice, NIH receives
written evidence and argument that establishes that the grant of the
license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: May 12, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2015-12005 Filed 5-18-15; 8:45 am]
BILLING CODE 4140-01-P